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Quality of Life in Patients 





Health evaluation implies assess multidimensional aspects of a person’s  
development, such as physical, social, psychological, and emotional features. It 
is important to consider all these factors to apply a needs-oriented each patient 
approach. Chronic skin diseases have a great impact on quality of life, even more 
than other chronic conditions. For example, hidradenitis suppurativa is estimated to 
impair quality of life more than cardiovascular disease, lung disease or endocrine dis-
eases. Multiple tools have been developed to measure health-related quality of life in 
patient, being the Dermatology Life Quality Index (DLQI) the most used. Psoriasis, 
hidradenitis suppurativa, acne, atopic dermatitis and hair disorders are those with 
the greatest impact on patients’ quality of life. Moreover, chronic skin conditions 
impair not only patients’ quality of life, but also cohabitants. Nevertheless, there is 
scarce information regarding the impact on their cohabitants. So, the objective of 
this chapter is to review the literature to assess the psychological and social effects of 
dermatological conditions both on patients and cohabitants.
Keywords: Acne, Alopecia, Atopic Dermatitis, Cohabitants, Hidradenitis 
Suppurativa, Psoriasis, Quality of Life
1. Introduction
Health evaluation implies assess multidimensional facets of a person’s develop-
ment, such as physical, social, psychological and emotional aspects [1]. It is impor-
tant to consider all these factors to apply a needs-oriented each patient approach. 
Chronic skin diseases have a great impact on quality of life, even more than other 
chronic conditions like asthma, epilepsy or diabetes [2]. Psoriasis, hidradenitis 
suppurativa, acne, atopic dermatitis and hair disorders are those with the greatest 
impact on patients’ quality of life [2–4].
Multiple tools have been developed to measure health-related quality of life 
in patient, being the validated Dermatology Life Quality Index (DLQI) the most 
used. It evaluates the impact of skin symptoms of dermatological conditions and 
their treatment on patient’s lives. The 10-item questionnaire covers the following 
aspects of patients’ quality of life: symptoms and feelings, daily activities, leisure, 
work or school, personal relationships, and treatment. Each question is scored 
from 0 to 3 (not at all/not relevant (0), a little [1], a lot [2], and very much [3]) and 
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reflects the extent to which the person’s life quality is adversely affected by the skin 
condition. The total score ranges from 0 to 30, and higher score reflects a greater 
impairment in patients’ life [5]. The DLQI punctuation is interpreted 0–1 = no 
effect at all; 2–5 = small effect; 6–10 = moderate effect; 11–20 = very large effect; 
21–30 = extremely large effect [6]. There are also other scales to assess anxiety, 
depression or sexual dysfunction that are also uses to evaluate different aspects of 
patients’ quality of life [6, 7]. The validated Hospital Anxiety and Depression Scale 
(HADS) is used to evaluate the prevalence of anxiety and depression. It is divided 
into two scales of seven items each. Scores equal or higher than 8 on the subscales 
are indicative of anxiety or depression [8]. The validated International Index of 
Erectile Function (IIEF-5) and the Female Sexual Function Index (FSFI-6) ques-
tionnaires are used to evaluate sexual dysfunction in men and women, respectively. 
Scores lower than 22 for IIEF-5 and lower than 20 are indicative of sexual dysfunc-
tion [9, 10]. Furthermore, to compare different diseases impact on quality of life 
or to compare several treatment improvements in patients’ life, quality-adjusted 
life-year (QALYs) or global disability-adjusted life years (DALYs) are used [11, 12].
Chronic skin conditions impair not only patients’ quality of life, but also cohabi-
tants. In fact, it has been described caregiver burnout syndrome, expressing with 
stress, anxiety or depression what may impair people’s life [13]. This means that the 
primary caregivers of a sick person are also affected by the disease. Although there 
is scarce information regarding the impact on cohabitants’ quality of life, recently 
the Family Dermatology Life Quality Index (FDLQI) has been developed. It is a 
10-item questionnaire that covers family member’s perception of a certain specific 
impact on his/her quality of life over the last 1 month. Each item is scored on a four-
point scale (0–3). The final scored is calculated by summing the scores of individual 
items and ranges from of 0 to 30. Higher total FDLQI scores indicate greater 
impairment of the family member’s quality of life [14]. FDLQI could be interpreted 
similarly to DLQI: 0–1 = no effect at all; 2–5 = small effect; 6–10 = moderate effect; 
11–20 = very large effect; 21–30 = extremely large effect.
The objective of this chapter is to review the literature to assess the psychological 
and social effects of dermatological conditions both on patients and cohabitants.
2. Material and methods
Search strategy. A literature search was performed using Medline, Scopus 
and Embase from conception to November 2020. The following search terms 
were used: ((Dermatology) OR (Skin diseases) OR (Alopecia) OR (Psoriasis) OR 
(Hidradenitis Suppurativa) OR (Acne) OR (Acne Inversa) OR (Atopic Dermatitis)) 
AND (Quality of Life).
Inclusion and exclusion criteria. The search was limited to: (i) human data, (ii) 
articles regarding impairment in quality of life in patients and cohabitants, (iii) articles 
written in English or Spanish. All types of epidemiological studies (clinical trials, 
cohort studies, case–control studies and cross-sectional studies) were included and 
analyzed. Reviews, guidelines, protocols, and conference abstracts were excluded. 
Skin conditions were selected regarding their high prevalence, their severity and their 
high impairment in quality of life. Psoriasis, hidradenitis suppurativa, atopic der-
matitis, acne and alopecia were included. Only studies using validate scales to assess 
impairment in quality of life were included.
Study selection. Two researchers (TMV and MSD) independently reviewed 
the titles and abstracts of the articles obtained in the first search to assess relevant 
studies. The full texts of all articles meeting the inclusion criteria were reviewed, 
and their bibliographic references were checked for additional sources. The 
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articles considered relevant by both researchers were included in the analysis. 
Disagreements about inclusion or exclusion of articles were subjected to discussion 
until a consensus was reached. If not reached, resolution was achieved by discussion 
with a third researcher (SAS).
Variables. The variables assessed were number of participants and cohabitants, 
assent tools used to evaluate quality of life, risk factors associated with impairment 
in cohabitants’ quality of life, general impairment in patients’ quality of life.
Target audience. Clinicians and research are the main audience of this review. 
Doctors should be aware to consider patients and cohabitant impairment in qual-
ity of life when making treatment decisions. Moreover, research should include 
validate measure of patients and cohabitants quality of life in their investigations.
2.1 Psoriasis
Psoriasis is a chronic, recurrent, multi-systemic inflammatory disease that 
mainly affects the skin and the joints [15]. It is a multifactorial disease caused by a 
combination of immunological imbalance, genetic associations and environmental 
factors [16]. Its prevalence around the word has been estimated from between 
0.51% and 11.43% [17], being more frequent in countries more distant from the 
equator [18]. In Europe, psoriasis prevalence is about 1.3% [19]. Furthermore, its 
incidence is increasing over the years [19, 20]. It has a bimodal age of onset (16 to 22 
and 57 to 60 years) [21] and it affects both sexes similarly [18].
Psoriasis is considered a major global health problem [22]. Although, the skin 
manifestations are commonly the only recognized symptoms of psoriasis [20], this 
disease is associated with multiple comorbidities such as arthritis, cardiovascular 
disease, metabolic syndrome, depression, anxiety or inflammatory bowel disease 
[23–26]. All of them contribute to increase the morbimortality in these patients. 
In fact, similar to many chronic inflammatory diseases, the risk of early mortality 
in patients with psoriasis is increased, especially due to cardiovascular events [27]. 
Likewise, the risk of mortality from cardiovascular disease is higher in patients 
with more severe psoriasis [28]. Patients with psoriasis are also at increased risk 
of mental problems. Rates of anxiety, depression and even suicide are increased in 
these patients [29]. Psoriasis can also influence the interpersonal and sexual health 
of people with psoriasis [30]. Psoriasis therefore impacts on physical, emotional, 
and social patient’s life [20]. Moreover, the economic burden of psoriasis is high, as 
in Europe the annual total cost per patient is between 6,000-12,000€ [31].
Furthermore, psoriasis has a great impact on cohabitants’ life [6, 7, 32]. The 
presence of psoriasis impaired the quality of life in almost 90% of the cohabitants. 
FDLQI scores of cohabitants are associated with the DLQI scores of the patients. 
Moreover, an increased body surface area affected, and the genital and scalp loca-
tion were associated with a higher FDLQI score while FDLQI scores were lower for 
cohabitants with higher professional/university education [6]. Disease severity and 
duration impact negatively on cohabitants’ quality of life, anxiety and depression 
[6, 32]. In addition, after getting psoriasis, a reduction in the frequency of sexual 
intercourse occurred in in more than 90% of the relationship and 40% of psoriasis 
partners suffer from sexual dysfunction [7, 32].
Multiple treatments are effective for treating psoriasis, including topical 
medications, phototherapy, oral systemic medications, and biologics [33]. Mild 
psoriasis can be treated with topical corticosteroids or corticosteroids plus vitamin 
D analogues. Moderate psoriasis needs to be treated with systemic treatments, such 
as methotrexate, acitretin or cyclosporine, or phototherapy. If psoriasis is severe 
or treatment-resistant, biologics are indicated. There is a wide range of biolog-
ics therapies for treating psoriasis: TNFα (etanercept, adalimumab, infliximab, 
Quality of Life Modifiers Due to Biological, Psychological, and Societal Factors
4
certolizumab), IL12/23 inhibitors (ustekinumab), IL23 inhibitor (guselkumab, 
risankizumab, tildrakizumab), IL17 inhibitors (secukinumab, ixekizumab, bro-
dalumab) [34]. The economic outcomes of these targeted treatments have been 
compared with non-targeted ones. The incremental benefits compared with no tar-
geted treatment are, in descending order: ixekizumab 1.68 QALYs, brodalumab 1.64 
QALYs, secukinumab 1.51 QALYs, ustekinumab 1.43 QALYs, infliximab 1.27 QALYs, 
adalimumab 1.15 QALYs, etanercept 0.97 QALYs, and apremilast 0.87 QALYs. Initial 
targeted treatment with IL-17 inhibitors seems to be the most effective treatment 
strategy for plaque psoriasis patients who have failed systemics [11].
2.2 Hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic, recurrent, debilitating inflamma-
tory skin disease of the hair follicle that usually presents after puberty with painful, 
deep-seated inflamed lesions in the apocrine gland-bearing areas of the body, most 
commonly the axillae, inguinal and anogenital regions [35]. A prevalence rate of 
around 1% has been estimated [36], of 0.03–1% in Europe [37–39] and of 0.053% in 
the USA [40].
Its etiopathogenesis is still elusive and may be of pivotal importance in improv-
ing patients and relative’s quality of life. Genetic susceptibility, smoking, obesity 
and hormonal disorders are major risk factors for the development of HS [41]. 
Moreover HS, has been associated with multiple physical comorbidities such as 
spondylarthritis, inflammatory bowel disease and increased cardiovascular risk 
[42, 43]. Moreover, HS impairs patients’ mental health. It has been related to higher 
levels of depression, anxiety, worse quality of life, sexual dysfunction and a higher 
suicide risk [44–47]. HS also has consequences on social relationships and profes-
sional careers, as high rates of absenteeism and unemployment have been reported 
in HS patients [43]. For all these reasons, HS is a stigmatizing and disabling disease 
that greatly impairs physical, emotional, and social patient’s life. Moreover, the 
economic burden of HS is high [48]. Direct medical costs due only to surgery are 
around £2,000 per patient per year in the UK [49]. Indirect costs, for expel associ-
ated with frequent and long-term absenteeism and disability, have also a great 
impact on the health system [50].
Moreover, HS has a great impact on cohabitants’ life as they are involved in 
patients’ caregiving [51–53]. A positive association between the Dermatology Life 
Quality Index (DLQI) and the Family Dermatology Life Quality Index (FDLQI) 
has been observed [52]. The most affected areas are emotional distress (depression, 
anxiety, embarrassment), social life and routine household expenditure [53]. In 
fact, patient’s anxiety and depression and higher score for negative affectivity are 
associated with a lower quality of life in their cohabitants [52]. Disease severity also 
impairs both patients and cohabitants life due to skin symptoms (disease duration, 
pain, more involved locations), the need of continuous care and more unpleasant 
treatments and a higher economic expenditure [51]. In addition, a great impact is 
found in partners or husband/wife compared with parents, leading to a potential 
effect on the couple relationships [51]. In fact, patient sexual dysfunction greatly 
impairs cohabitant’s quality of life [52]. On the other hand, higher educational level 
and an early diagnosis and treatment have a positive impact on patients and their 
partners’ life [51–53].
HS therapy is often challenging and requires the combination of medical and 
surgical treatments [54, 55]. Medical treatment of mild disease consists in topical 
clindamycin 1% solution/gel twice a day for 12 weeks or, for a more widespread 
disease, tetracycline 500 mg daily for 4 months. If patient do not respond or for 
moderate-to-severe disease, clindamycin 300 mg with rifampicin 600 mg daily for 
5
Quality of Life in Patients with Skin Disease and Their Cohabitants
DOI: http://dx.doi.org/10.5772/intechopen.97450
10 weeks would be considered [56]. Adalimumab, a monoclonal antibody against 
tumor necrosis factor-α, is the only biologic agent currently available for treat-
ing moderate to severe HS, but a primary or secondary lack of response has been 
observed in some patients [57]. New insights into the pathogenesis of HS reveal an 
inflammatory cytokine profile including elevated levels of (TNF)-α, interleukin 
(IL)-1ß, IL-17 or interferon (IFN)-γ and other biologic treatments such as berme-
kimab, bimekizumab, brodalumab, guselkumab, risankizumab or secukinumab are 
being tested in clinical trials [58]. There is scarce evidence regarding cost-effective-
ness therapies in HS. It has been estimated that the incremental cost-effectiveness 
ratio for adalimumab versus standard care was around £30,000 per QALY gained 
[59]. Nevertheless, it cost-effectiveness was highly susceptible to the health states’ 
utility values, the treatment discontinuation and the resource utilization [60].
2.3 Acne
Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit that 
usually presents at adolescence with comedones (blackheads and whiteheads), 
papules, pustules, nodules, cysts and scars. The most affected areas corresponds to 
the highest density of pilosebaceous units (face, neck, upper chest, shoulders, and 
back) [61]. It is a prevalent condition that involves 85% of adolescents and 6–10% 
of the general population [62].
Acne is a multifactorial disease resulting from androgen-induced disturbed 
sebaceous gland activity associated with increased sebum production and altera-
tions in sebum fatty acid composition, altered keratinisation, inflammation, 
Propionibacterium acnes colonization of hair follicles and dysfunction of the innate 
and adaptive immunity [63]. Genetic susceptibility, air pollution, aggressive skincare 
products, corticosteroids and hormonal products are risk factors to develop acne. The 
role of nutrition in acne pathogenesis is still controversial [64]. Acne is associated 
with physical disability due to painful skin lesions. Moreover, it usually affects visible 
areas, with risk of permanent scarring and aesthetic consequences. In fact, acne is 
associated with high rates of anxiety, depression and even suicide [65, 66]. People 
with acne are also more prone to have social phobia [67].
Acne not only impairs patients’ life but also their cohabitants. More than 90% 
of people leaving with acne patients have impaired their quality of life. A posi-
tive correlation between FDLQI in cohabitants and DLQI in patients is observed. 
Furthermore, patients’ level of depression and anxiety are also associated with their 
cohabitants’ [68].
Acne treatment is based on disease severity, patient preference, site of 
involvement, age of the patient and tolerability. Topical therapies may be used as 
monotherapy, in combination with other topical agents or in combination with 
oral agents in both initial control and maintenance. The most employed topical 
products are benzoyl peroxide, salicylic acid, antibiotics, combination antibiotics 
with benzoyl peroxide, retinoids, retinoid with benzoyl peroxide, retinoid with 
antibiotic, azelaic acid, and sulfone agents. Systemic antibiotics are used in moder-
ate to severe inflammatory acne and should be used in combination with a topical 
retinoid and benzoyl peroxide. Tetracycline, mainly doxycycline and minocycline, 
are the most effective antibiotics. Oral contraceptives can improve acne for many 
women, mainly in those with clinical or laboratory signs of hyperandrogenism. Oral 
isotretinoin is indicated for severe acne or moderate treatment-resistant acne [69].
The effectiveness and cost effectiveness of isotretinoin are well proven as its cost 
per QALY of £898 ($US l3 74) is affordable [70]. Dermatologist treatment appears 
cost-effective related to producing additional QALYs at a cost of $40,000 per QALY 
gained [71].
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2.4 Atopic dermatitis
Atopic dermatitis (AD) is a common and chronic inflammatory skin disease. It 
is characterized by recurrent eczematous lesions and intense itch which develop in 
people of all ages and ethnicities. The prevalence of AD has been estimated around 
12% in children and 7% in adults in United States [72]. It is considered the leading 
non-fatal health burden attributable to skin diseases [73]. The etiopathogenesis 
of AD is not completely understood. However, most studies agree that skin bar-
rier dysfunction and immune dysregulation play a key role in the development of 
AD [74, 75]. Genetic polymorphisms in the filaggrin gene, which encode a major 
structural protein in the stratum corneum, upregulation of Th2 cytokines, such as 
IL-4 and IL-13, changes in the skin microbiome and altered lipid composition are 
thought to be responsible for the appearance of pruritus and skin lesions in patients 
suffering from AD [75–78].
AD is frequently associated with food allergy, asthma and rhinitis, which is also 
known as the “atopic march”. This concept refers to the propensity for AD to begin 
early in life and be followed by the serial incidence of food allergy, asthma, and 
hay fever [79]. Other associated conditions include eosinophilic esophagitis [80], 
allergic contact dermatitis [81], cardiovascular disease [82] and infections [83, 84].
Skin lesions and severe symptomatology, including severe itch and skin pain, 
contribute to an impaired quality of life in patients suffering from AD. Psychosocial 
distress, stigma, sleep disturbance avoidance of social interaction are consequences 
of AD [85]. Significantly poorer dermatology-related quality of life scores have been 
found in patients with AD: higher DLQI [86] and Children’s DLQI [87], greater 
Skindex affectation [88] and itch-related quality of life [89]. Different general qual-
ity of life scores are also affected in patients with AD [86, 87, 89]. Furthermore, the 
impact on quality of life is not restricted to the patient itself, but also affects to their 
cohabitants. It has been shown that parents of children with AD have lower quality-
of-life scores [90–92] and that AD influences marital conflicts [93]. Regarding the 
sexual health, there is evidence that AD have a strong impact in sexual behavior. 
The involvement of visible areas and sensual areas leads to lower quality of life 
indexes and higher burden scores in patients with AD [94]. Moreover, people with 
more severe AD have a greater impact on sexuality [94, 95].
Given its high burden, AD have been associated with high QALY loss, even 
higher than autoimmune disorders, diabetes, food allergy and heart disease in both 
males and female [96]. Moreover, six-dimensional health state short form (SF-6D) 
score, an utility score which ranges from 0 (worst health) to 1 (best health) was 
estimated to 0.63 in severe AD. This was lower than SF-6D in high blood pres-
sure (0.63), diabetes (0.65) and similar to anxiety, depression and heart disease 
(0.63) [96].
The treatment of AD follows a stepwise approach that is tailored according to 
disease severity and extension [85, 97]. Patient’s education and basic skin care must 
be carried out in all patients, including those without active skin lesions. It consists 
of the frequent application of skin moisturizers, warm baths or showers using 
non-soap cleansers and avoidance of skin irritants. For mild and localized disease, 
treatment involves the use of topical corticosteroids (TCS) and topical calcineurin 
inhibitors (TCI). For moderate-to-severe and extensive disease, phototherapy or 
systemic drugs are indicated. Systemic immunosuppressants, such as cyclospo-
rine, methotrexate, azathioprine and mycophenolate mofetil can be used [75, 85]. 
Dupilumab, a monoclonal antibody which acts as a targeted therapy for AD, is 
currently the most effective therapy por severe AD. It acts through the blockage of 
the IL-4 receptor alpha-chain [85, 98]. Emerging therapies include anti IL-13 and 
anti IL-31 antibodies, JAK inhibitors, and inhibitors of PDE-4 [85, 98].
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Finally, AD places a high financial burden on patients, families and society 
through direct medical costs and decreased productivity. Taking this into account, 
a conservative estimate of the annual costs of atopic dermatitis in the United 
States (2015) is $5.297 billion [99]. Regarding the current development of novel 
treatments, which involve higher costs [100], these costs is likely to increase over 
the time.
2.5 Alopecia
Alopecia is a heterogeneous group of common skin disorders. This group can be 
divided into two minor groups: a) Non-cicatricial alopecia: Follicular epithelium 
is not replaced by connective tissue, so it is potentially reversible; b) Cicatricial 
alopecia: Follicular epithelium is replaced by connective tissue, so it is assumed that 
permanent injury of the follicular stem cell region has occurred.
2.5.1 Non-cicatricial alopecia
Many different skin conditions can be classified into this category. Most com-
mon and most representative non-cicatricial alopecia will be reviewed below.
2.5.1.1 Androgenetic Alopecia (AGA)
AGA is an androgen-dependent hereditary disorder resulting from the conver-
sion of scalp terminal hairs into miniaturized vellus hairs in a characteristic pattern. 
Androgens act on the epithelial cells of genetically susceptible hair follicles in 
androgen-dependent areas, leading to follicular miniaturization [101]. Its frequency 
and severity increase with age, with at least 80% of Caucasian men and 50% of 
women showing signs of AGA by age 70 years [102, 103]. In male pattern hair loss, 
there is a progressive loss of hair in the frontal and bitemporal line, and also in the 
vertex. In the female pattern hair loss, the frontal hairline is spared with a diffuse 
central thinning of the crown.
In some studies, AGA has associated to age and family history of AGA. Moreover, 
some factors related to metabolic syndrome have also been related to AGA in both 
genders: Hypertension, diabetes mellitus and waist circumference [104].
As AGA is frequent and affects a visible area such as the scalp, it can lead to a 
significant impairment in the quality of life and social inhibition in patients. There 
is evidence of the impairment in quality-of-life scores in both males and female suf-
fering from AGA: DLQI [105–107], Hairdex scale [105] and Skindex-29 scale [106]. 
Moreover, AGA has a negative impact on sexual function in premenopausal women, 
reflected in a decreased FSFI compared to healthy females [108].
Only two therapeutic agents have been approved by the Food and Drug 
Administration and European Medicines Agency for the treatment of AGA: Topical 
minoxidil (in both males and females), and oral finasteride (in males) [109]. 
Minoxidil was first introduced as an oral treatment for severe hypertension in the 
1970s [110]. When hypertrichosis was observed as a side effect of this medication, 
both topical and oral formulations of minoxidil were developed to treat alopecia. 
Minoxidil changes the micro-environment of the hair follicle, inducing a prolonged 
anagen phase and increased hair growth. Most common presentations of topical 
minoxidil include 2% and 5% lotions which are applied 1 ml/12 hours. Although 
oral minoxidil seems to be effective to treat AGA, it is not yet approved [111]. Oral 
finasteride is approved for AGA in men with a dosage of 1 mg/24 hours. It acts 
through the inhibition of 5-alpha reductase and is effective and safe [109] in the 
treatment of AGA.
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2.5.1.2 Alopecia Areata (AA)
AA is a common inflammatory hair loss, characterized by an autoimmune-
mediated hair follicle destruction, due to the upregulation of inflammatory 
pathways. The lifetime incidence of AA is approximately 2% worldwide [112]. The 
etiology is still not fully understood, but the loss of immune privilege in the hair 
follicle seems to play a crucial role in the development of AA [113]. Clinical features 
of AA vary from the appearance of small, well-circumscribed patches of hair loss to 
a complete absence of body and scalp hair.
As AA is an autoimmune disorder, patients suffering from AA have a higher risk 
of developing autoimmune diseases: thyroid disorders [112, 114], with an incidence 
in AA between 2,3-14,6%; diabetes mellitus, with an incidence in AA between 
0,4-11,1% [115]; and vitiligo, with an incidence in AA between 1,8-7,0% [115] are 
some of the most common. AA have also been associated with atopic diseases, 
metabolic syndrome, Helicobacter Pylori infection, and vitamin D deficiency 
[116]. Moreover, a 66–74% of lifetime prevalence of psychiatric disorders have 
been reported in AA patients, with a 38–39% lifetime prevalence of depression and 
a 39–62% prevalence of generalized anxiety disorder [117–120].
Regarding the quality of life in people suffering from AA, there is increasing 
evidence of the strong impact of AA in quality-of-life scores, which affects up to 
76.7% of children and 77.6% of adults [121]. Impairments in DLQI as well as in 
alopecia specific scores have been reported [115, 121, 122]. Role-emotional, mental 
health and vitality domains seem to be the most affected [121]. Moreover, scalp 
involvement, anxiety and depression have a negative impact on the quality of life of 
patients with AA [121]. AA also impacts on sexual quality of life [123]. One study 
showed that both males and females suffering from AA had decreased sexual qual-
ity of life with low Sexual Quality of Life for Females (SQOL-F) and Sexual Quality 
of Life for Males (SQOL-M) scores. In this study, men strongly identified with the 
statement “I fell anxious” and women with the statement “I feel embarrassed”.
Preliminary outcomes of a research conducted in the Hospital Virgen de las 
Nieves (Granada, Spain), which were presented at the national congress of the 
Spanish Dermatology Academy showed also a significant burden in cohabitants of 
patients with AA. Cohabitants of patients with AA had high FDLQI scores, which 
correlated to DLQI from patients. Anxiety in cohabitants also showed correlation 
with the time of evolution of the disease [124].
There are different therapeutic options for AA, depending on the age of the 
patient and the extension of the disease. Briefly, in adult patients suffering from 
isolated patches of hair loss or less than 25% of scalp hair loss are the best candi-
dates to therapy with intralesional injections of potent corticosteroids (such as 
triamcinolone). In the case of adult patients who refuse the injections and children, 
potent topical corticosteroids (betamethasone, clobetasol) are considered the 
first-line therapy. An alternative for mild cases is the use of topical anthralin. When 
AA is extensive, systemic drugs are recommended. Systemic corticosteroids taken 
in low doses can be effective but involve serious long-term adverse events. Other 
systemic immunosuppressive agents can be useful in AA: methotrexate or azathio-
prine. JAK inhibitors (tofacitinib, baricitinib) are novel promising therapies for 
severe cases of AA [125, 126].
2.5.2 Cicatricial alopecia
A wide variety of diseases can be classified into this group, both primary skin 
diseases and secondary cicatricial alopecia. Given that most of cicatricial alopecia 
are relatively uncommon, there is scarce evidence regarding their comorbidities and 
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their treatment. Moreover, almost any studies report data about the impairment in 
quality of life associated with these skin disorders.
Few studies address the issue of quality of life in patients with Frontal Fibrosing 
Alopecia (FFA) [127]. FFA is a cicatricial alopecia, typically appearing in post-
menopausal woman, characterized by slowly progression of hair loss in the frontal, 
temporal or frontotemporal scalp and eyebrows. Hair follicles show perifollicular 
erythema and scale. Patients with FFA have been found to show impairments in 
DLQI, and anxiety and depression scores [127].
Preliminary outcomes of a research conducted in the Hospital Virgen de las 
Nieves (Granada, Spain), which were presented at the national congress of the 
Spanish Dermatology Academy showed a significant burden in cohabitants of 
patients with FFA. Cohabitants of patients with FFA had high FDLQ ) scores, which 
correlated to DLQI from patients. Anxiety in cohabitants also showed correlation 
with the time of evolution of the disease. However, the impact on the quality of life 
in cohabitants of patients with FFA was lower than the impact on the cohabitants of 
patients with AA [124].
3. Discussion
Skin diseases have a great impact on patients and cohabitants quality of life. 
Clinicians should be aware of this issue so they can provide an individualized 
medicine, targeting not only the visible symptoms of the disease but also the impact 
on quality of life. Researchers should also include quality of life impairment scales 
for patients and cohabitants to measure the effectiveness of treatments. Universal 
scales are needed to homogenize results. Further research regarding skin conditions 
should include the impact of both patients and cohabitants’ quality of life assessed 
by validate scales. Moreover, healthcare policy should also consider not also 
patients’ needs but also cohabitants’.
The most common tools to assess impairment in quality of life were the DLQI 
(for patients) and the FDLQI (for cohabitants), Table 1. HS and psoriasis are the 
diseases that have a greater impact on patients and cohabitant quality of life. The 
media DLQI scores for HS was 13.34 points and the media FDLQI was 9.76 points 
[51–53]. Psoriatic patients reported a media of 10.79 points in the DLQI and their 
cohabitants reported a media of 12.8 points in the FDLQI [6, 7, 32]. The greater 
impairment of this disease could be explained because of the symptoms, chronicity 
and comorbidities associated. The clinical manifestations of HS cause pain, itching, 
malodor and suppuration, among other symptoms, which make life difficult for 
patients [35]. Pain is one of the most important problems in patients with HS, usu-
ally related to the inflammation of the nodules. Psoriatic plaques are also associated 
with itching and pain what cause an important physical burden in patients [15]. The 
lesions of these disease frequently appear on the genital area, having an impact on 
sexual life [15, 35]. The sexual impairment could also explain the great cohabitants 
impairment of quality of life [6, 52], apart from the chronicity of this disease and 
the caregiver burnout syndrome. The following disease with higher points in the 
DLQI was AD (media of 10.78) [ 86, 87, 89]. This could also be explained because 
of the itching and the sleep disorder associated with this disease [79]. Acne and 
alopecia were scored with the lowest rate quality of life impairment. Acne patients 
scored a media of 7.56 points in the DLQI and their cohabitants a media of 6.46 in 
the FDLQ [68]I. This could be explained because it is a disease that usually happens 
in adolescent and it is temporary [65]. Alopecia patients recorded a media of 6.1 
points in the DLQI and their cohabitants a media of 6.13 points [124]. This might 

























tools used to 
evaluate quality 
of life
Patients Cohabitant Risk factor associated with 
impairment in cohabitants’ 
quality of life
General impairment in patients’ 
quality of life
Psoriasis Martinez-Garcia 
E et al. 2014
34/49 DLQI 12 (range 
1–28)
— Negative factors: DLQI, marital 
status, cohabitants’ anxiety, severe 
psoriasis, a long disease duration, 
genital and scalp location.
Protective factors: Higher 
professional/university education
Increased risk of other diseases: 
arthritis, cardiovascular disease, 
metabolic syndrome, inflammatory 
bowel disease.
Increased risk of mental problems: 
anxiety, depression, suicide.
Impaired social life: interpersonal and 
sexual health., economic burden.












Halioua, B et al. 
2020
184/184 DLQI 9.57 (6.35 
SD)
— Negative factors: patients’ quality 
of life, cohabitants’ mental health, 
patient disease severity





Pita C et al. 2020
27/27 DLQI 13.88 
(SD 9.53)
— Negative factors: patients’ BMI, 
IHS4, impairment in patients’ 
quality of life, patients’ negative 
affectivity, patients’ depression, 
sexual dysfunction, partners’ 
sexual dysfunction
Physical comorbidities: 
spondylarthritis, inflammatory bowel 
disease and increased cardiovascular 
risk.
Mental health: depression, anxiety, 
suicide.
Impaired social life: sexual dysfunction,
high rates of absenteeism and 
unemployment, economic burden










Wlodarek K et 
al. 2020
50/50 FDLQI — 8.7 (SD 6.8) Negative factors: patient’s and 
partner’s age, Hurley stage, HSSI
Marasca C et al. 
2020
35/70 DLQI 12.8 (SD 
4.48)
— Negative factors: DLQI, Hurley 
stage, partner relationship
Protective factors: Higher 
professional/university education









































tools used to 
evaluate quality 
of life
Patients Cohabitant Risk factor associated with 
impairment in cohabitants’ 
quality of life
General impairment in patients’ 
quality of life
Acne Martinez-Garcia 
E et al. 2014
62/66 DLQI 7.56 
(range 
0–29)
— Negative factors: impairment 
in patients’ quality of life, acne 
duration, cohabitant’s anxiety 
level.
Physical disability: painful lesions.
Mental health: high rates of anxiety, 
depression and suicide.
Impaired social life: aesthetic 
consequences, social phobia.




Xu X et al. 2019 559 / 559 IDQOL 8.76 (SD 
2.6)
— Negative factors: Higher CDLQI 
and IDQOL, severity of the 
disease, and children’s age.
Age and severity of the disease was 
related to lower quality of life in 
children. Patients have an increased 
risk of food allergies, asthma, hay 
fever, eosinophilic esophagitis, allergic 
contact dermatitis, cardiovascular 
disease and infections.
CDLQI 8.76 (SD 
2.2)
—
RAND-36 — 38.52 (SD 
7.16)
Ezzedine K et al. 
2020
399 / 399 CDLQI 8.7 (SD 
7.1)
— Negative factors: Children’s age, 
higher CDLQI and DLQI, shorter 
disease duration, younber parents.
DLQI 12.8 (SD 
11.1)
—
ABS-F — 10.0 (SD 8.0)
Gieler U et al. 
2017
64 / 64 GDS, QPCAE. — . Negative factor: Being a single 
mother of a child with atopic 
dermatitis led to higher perceived 
stress in the family and less 
life-satisfaction when compared 
to mothers with partners.
Jang HJ et al. 
2016
78 / 78 DFI — — Negative factors: Severity of the 
disease, children’s female gender, 
parent’s stress and negative affect 

























tools used to 
evaluate quality 
of life
Patients Cohabitant Risk factor associated with 
impairment in cohabitants’ 
quality of life





S et al. 2020 
(preliminary 
outcomes)
16 / 16 DLQI 6.5 — Negative factors: The evolution 
time of the diseases led to higher 
anxiety and depression scores 
in cohabitants. Higher FDLQI 
correlates to higher anxiety and 
depression scores
Patients with AA have higher risk of 
thyroid disorders, diabetes mellitus, 
vitiligo, atopic diseases, metabolic 
syndrome, Helicobacter Pylori 
infection, and vitamin D deficiency. 
There is a 66–74% of lifetime 
prevalence of psychiatric disorders 
(depression and prevalence of 
generalized anxiety disorder).






S et al. 2020 
(preliminary 
outcomes)
15 / 15 DLQI 5,7 — Negative factors: The evolution 
time of the diseases led to higher 
anxiety and depression scores 
in cohabitants. Higher FDLQI 
correlates to higher anxiety and 
depression scores
There is scarce evidence regarding 
the comorbidities of FFA. Patients 
with FFA have been found to show 
impairments in DLQI, and anxiety and 
depression scores.
FDLQI — 5
ABS-F: Atopic dermatitis Burden Scale-Family; CDLQI: Children’s Dermatology Quality of Life Index; DFI: Dermatitis Family Impact questionnaire; DLQI, Dermatology Life Quality Index; FDLQI, 
Family Dermatology Life Quality Index; GDS: General Depression Scale; HSSI, Hidradenitis Suppurativa Severity Index; IDQOL: Infant’s dermatitis quality of life; IIEF-5, International Index of Erectile 
Function; QPCAE: Questionnaire for Parent so Children with Atopic Eczema; SFI-6, Female Sexual Function Index;.
Table 1. 
Articles regarding quality-of-life impairment in patients with skin diseases and cohabitants.
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some types of alopecia, such as alopecia areata, are not chronic and patients can be 
completely recovered from its disease [125].
Regarding psychological impact of patients and cohabitants, HADS-A and 
HADS-D are the most frequent scales used, Table 2. The highest rates of patient’s 
anxiety are reported for HS (9.51) and psoriasis (8.82), followed by frontal fibrosing 
alopecia (7.5), acne (6.9) and alopecia areata (6.6). The highest rates of cohabitants 










Garcia E et al. 
2014














Halioua, B et 
al. 2020
184/184 MCS-12 41.94 (SD 10.35) 45.50 (SD 
11.00)
PSC-12 45.57 (SD 5.63) 44.92 (SD 5.75)



















27/27 HADS-Anxiety 9.51 (SD 4.89) 7.22 (SD 4.20)
HADS-
Depression
7.70 (SD 5.11) 5.14 (SD 4.52)
Atopic 
Dermatitis
Gieler U et al. 
2017
64 / 64 SSQ, SWLS. — —
Jang HJ et al. 
2016
78 / 78 SWLS, PANAS — —
Acne Martinez-
Garcia E et al. 
2014
62/66 HADS-A 6.29 (range 0–15) 6.91 (range 
1–19)






et al. 2020 
(preliminary 
outcomes)









et al. 2020 
(preliminary 
outcomes)




HADS, Hospital Anxiety and Depression Scale; MCS-12, Mental Health Subscale; PANAS: Positive Affect and 
Negative Affect Schedule; PCS-12, Physical Health Subscale; SWLS: Satisfaction With Life Score; SSC: Short Stress 
Questionnaire.
Table 2. 
Articles regarding psychological impairment in patients with skin diseases and cohabitants.
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anxiety are reported for psoriasis (8.06), followed by HS (7.22), acne (6.91), alope-
cia areata (6.5) and frontal fibrosing alopecia (4.5). Depression was rated lower than 
anxiety in all diseases. Patients reported the highest rates for HADS-Depression in 
HS (7.7) and psoriasis (6.15), followed by alopecia areata (4.9), frontal fibrosing 
alopecia (4.1) and acne (2.47). Cohabitants reported the highest rates for HADS-
Depression in alopecia areata [6], HS (5.14), psoriasis (4.73), acne (4.23) and frontal 
fibrosing alopecia. Up to our knowledge, there are no reports regarding the impact 
of AD in cohabitants anxiety and depression. In agreement with DLQI and FDLQI 
scores, psoriasis and HS are the diseases that have the greatest impact on patients 
and cohabitants anxiety [ 6, 7, 32, 51–53]. Regarding depression, patients’ reports 
are in agreement with anxiety and DLQI scores. Nevertheless, cohabitants reported 
the highest scores for anxiety in alopecia areata [124]. This might be due because 
most alopecia areata patients are children and their hair loss negatively affect their 
parent’s psycho [112].
4. Conclusion
Since skin lesions are visible and can generate unpleasant sensations, such 
as itching or pain, skin diseases are a major cause of decreased quality of life. In 
addition, the involvement of areas with a high emotional burden, such as the genital 
area, scalp o facial area can lead to social inhibition, anxiety and depression. Studies 
focused on the evaluation of the quality of life of patients and cohabitants with skin 
diseases and their co-habitants are necessary to objectify the great burden they bear. 
Therefore, it seems necessary to make a comprehensive approach to skin diseases, 
taking into account not only the medical aspect, but also the emotional and the 
quality of life of both patients and cohabitants.
The holistic approach of the skin disease requires the complete evaluation of 
patients and cohabitants, from the biological, psychological and social point of 
view. This approach should include specific evaluations of quality of life and related 
disorders in all patients and cohabitants, which will lead to a better quality of the 
health of the populations. Moreover, therapeutic methods aimed at improving the 
quality of life such as patient schools, cognitive-behavioral strategies or mindful-
ness should be implemented in the daily clinical practice to treat not only the 
biologic, but also the social and psychologic manifestations of skin diseases.
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